Global Carglumic Acid Industry

Global Carglumic Acid Industry

  • April 2021 •
  • 176 pages •
  • Report ID: 6044232 •
  • Format: PDF
Abstract:
- Global Carglumic Acid Market to Reach $167.4 Million by 2027
- Amid the COVID-19 crisis, the global market for Carglumic Acid estimated at US$109.3 Million in the year 2020, is projected to reach a revised size of US$167.4 Million by 2027, growing at aCAGR of 6.3% over the period 2020-2027. Tablet, for Suspension, one of the segments analyzed in the report, is projected to record 6.1% CAGR and reach US$96.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Tablet, Orally Disintegrating segment is readjusted to a revised 6.5% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $29.6 Million, While China is Forecast to Grow at 9.5% CAGR
- The Carglumic Acid market in the U.S. is estimated at US$29.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.8 Million by the year 2027 trailing a CAGR of 9.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

- Select Competitors (Total 38 Featured) -
  • Aktteva Biopharma LLP.
  • Apothecon Pharmaceuticals Pvt Ltd
  • Biophore India Pharmaceuticals Pvt Ltd
  • Civentichem LLC
  • Dipharma Francis S.r.I
  • Dipharma S A
  • Manus Aktteva Biopharma LLP
  • NOVITIUM PHARMA LLC
  • NURAY CHEMICALS
  • Recoedati S.p.A
  • Recordati Rare Diseases Inc
  • Suven Life Sciences Limited